Breast Cancer :: FDA approves Glaxo’s Tykerb for advanced breast cancer patients
The US Food and Drug Administration (FDA) approved Tykerb (lapatinib), a new targeted anti-cancer treatment, to be used in combination with capectabine (Xeloda), another cancer drug, for patients with advanced, metastatic breast cancer that is HER2 positive (tumors that exhibit HER2 protein).